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frequently smokers than never-smokers (p = 0.046). In addi-
tion, TT genotype exhibited increased state anxiety scores 
compared to carriers of the C allele (p = 0.037).  Conclusions: 
Our results provide evidence for an involvement of the func-
tionally relevant SNP rs16147 in the pathophysiology of to-
bacco dependence. Further studies are needed to confirm 
our findings.  Copyright © 2012 S. Karger AG, Basel
 Introduction
 Tobacco smoking is a major health problem with ex-
tensive consequences for persons concerned, and the so-
ciety in general  [1, 2] . Biological, political and psycho-
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 Abstract
 Background: Neuropeptide Y (NPY) is a strong candidate 
gene regarding the pathophysiology of tobacco depen-
dence. It has been associated with various addictive and psy-
chiatric disorders, and closely interacts with the brain reward 
system. The aim of the present study was to test for associa-
tion between a functional genetic variant in the NP-Y pro-
moter gene (SNP rs16147) and tobacco smoking.  Methods: 
In a population-based case-control multicenter study de-
signed for tobacco addiction research, a total of 550 Cauca-
sian current smokers, and 544 never-smokers were geno-
typed for SNP rs16147 and behaviorally characterized with 
the State-Trait Anxiety Inventory (STAI).  Results: Subjects 
with TT genotype of the SNP rs16147 were significantly more 
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logical factors are involved in smoking behavior and to-
bacco dependence  [3, 4] . Twin studies have consistently 
estimated heritability of around 50% for tobacco depen-
dence  [5, 6] . Thus, genetic factors have a substantial con-
tribution to the tobacco dependence etiology. Several dif-
ferent genes are associated with tobacco smoking; recent-
ly, genome-wide association studies investigated several 
promising genetic determinants of tobacco dependence 
and found strongest genetic contribution to nicotine de-
pendence from variation in the nicotinic receptor sub-
units and in nicotine metabolism  [7–9] . However, varia-
tion within these genes accounts for only a small propor-
tion of the risk for developing tobacco dependence, which 
implies that many genes seem to be involved in this com-
plex behavior and disease  [10] . Nicotine and other sub-
stances from tobacco affect brain functions through 
modifying different neurotransmitter systems, and nico-
tine is the major addictive substance in tobacco  [11] . The 
rewarding effects of nicotine (e.g. relief of anxiety and 
arousal), withdrawal symptoms (e.g. craving, irritability, 
dysphoric or depressed mood, anxiety, restlessness, in-
creased appetite or weight gain and insomnia), and envi-
ronmental factors (e.g. stress) are the main factors which 
contribute to the consolidation of the tobacco depen-
dence  [11] . Nicotine mainly binds to nicotinic acetylcho-
line receptors containing the   4  and   2  subunits, often in 
combination with the   6  subunit, which are located with 
the highest concentrations in the mesolimbic dopami-
nergic reward system in the brain  [12, 13] . Nicotine is the 
major addictive component of tobacco and a potent ago-
nist of neuronal nicotinic receptors (AChRs) thereby 
stimulating dopamine (and norepinephrine) release  [14] . 
Hence, the dopaminergic system is considered a major 
pathway for tobacco use and development of tobacco de-
pendence  [15] .
 Neuropeptide Y (NPY), a 36-amino-acid peptide, is 
expressed at high levels within the nervous system  [16, 
17] . The NPY gene (NP-Y) is a potential candidate gene 
involved in nicotine dependence because NP-Y has been 
shown to increase extracellular dopamine levels dose-
dependently in the shell region of the nucleus accumbens 
in rats  [18] . This indicates that NP-Y could play an im-
portant role in drug reinforcement by modulating dopa-
mine levels in the brain reward system. On the other 
hand, the anxiolytic neuropetide NP-Y is also known as 
endogenous regulator of appetite and anxiety  [19–21] , 
which is both affected through tobacco smoking, and 
nicotine withdrawal  [11, 22, 23] . Hence, NP-Y gene vari-
ations have been associated with negative effects, and 
numerous psychiatric diseases in a number of studies 
 [20, 24, 25] . Furthermore, several studies suggested a 
possible involvement of the NP-Y system in the neuro-
biological effects of different abused substances includ-
ing alcohol  [26] , methamphetamine  [27] , and smoking 
behavior  [28] .
 In summary, the NP-Y system has been shown to mod-
ulate drug intake behavior, anxiety, and positive reward-
ing properties. Taking these findings together, the NP-Y 
gene may be an interesting candidate gene to gain new 
insights into the pathophysiology of tobacco dependence. 
In particular, the (promotor) single nucleotide polymor-
phism (SNP) rs16147 has been reported to influence NP-Y 
gene expression on the level of mRNA and protein and 
accounts for a relevant part of differential expression of 
NPY in vitro  [24, 25, 29] . We therefore analyzed whether 
this functional genetic variant in the NP-Y promoter gene 
is associated with cigarette smoking in an ethnically ho-
mogenous sample of healthy Caucasian subjects from 
Germany.
 Methods
 Data Collection
 For case-control association analysis, 550 current smokers 
(Fagerström test 5–10 points) and 544 never-smokers (max. 20 
cigarettes/lifetime), of whom 464 subjects were male and 630 were 
female (entire sample n = 1,094), all were genotyped. Data were 
collected in seven recruitment centers throughout Germany (De-
partments of Psychiatry at the University of Aachen, Berlin, Bonn, 
Düsseldorf, Erlangen, Mainz, Mannheim) between the years 2007 
and 2009. Inclusion criteria for subjects were: German origin and 
mother-tongue level German and grandparents of subjects were 
required to be born in Germany or in a country adjacent to Ger-
many. Subjects with non-German ethnicity were not included. 
Further details of recruitment, testing procedures, inclusion/ex-
clusion criteria, and characterization of this multicenter study on 
nicotine dependence and smoking-related behavior have been de-
scribed previously  [23, 30] .
 Inclusion/exclusion criteria were assessed through a medical 
examination, a standardized psychiatric interview (SCID-1), 
questionnaires, drug screen, alcohol testing and CO measure-
ment. The present study was approved by the ethics committees 
of all participating centers; subjects were included in the study 
after they had given written informed consent.
 Psychometric Measures
 The absence of psychiatric axis-I comorbidity was verified 
with the Structured Clinical Interview  [31] which is based on 
DSM-IV criteria (American Psychiatric Association, 2000). The 
Fagerström Questionnaire for Nicotine Dependence  [32] was 
used as a measure for the level of nicotine dependence  [33] and 
Heaviness of Smoking Index (HSI-G)  [34] . Nicotine craving was 
measured via self-report with the Questionnaire of Smoking
Urges (QSU)  [35] (QSU German version  [36] ). Anxiety was as-
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sessed with the trait version of the State-Trait Anxiety Inventory 
(STAI  [37] ; STAI German version  [38] ). Depressive symptoms 
were measured with the Beck Depression Inventory (BDI  [39] ; 
BDI German version  [40] ). Subjective experience of stress was 
measured by the Perceived Stress Scale (PSS  [41] ). To control for 
alcohol use the Alcohol Use Disorders Identification Test (AUDIT 
 [42] ; AUDIT German version  [43] ) was used.
 DNA Preparation and Genotyping
 Genotyping was done at the Cologne Center for Genomics 
(CCG), University of Cologne. DNA from fresh frozen EDTA 
blood was prepared with Qiagen FlexiGene DNA Kit according to 
the manufactory protocol and normalized based on RNase P copy 
number measurement using the TaqMan RNase P assay from Ap-
plied Biosystems  (Foster City, Calif., USA). The SNP rs16147, a 
functional NP-Y promoter variant, was chosen to cover the func-
tional expression of brain NP-Y. Genotyping was performed with 
SNPstream SNP genotyping assays. Genotyping call rates were 
99%. All laboratory procedures were carried out blind to case-
control status.
 Data Analysis
 The baseline demographics and clinical characteristics were 
compared between smokers and non-smokers. Descriptive statis-
tics were calculated with t tests for independent samples and are 
given with mean and standard deviation. The Levene test was 
used to assess the homogeneity of variance. Associations between 
the genotype and smoking behavior were evaluated using the   2  
test, while the interaction effect of genotype and smoking behav-
ior on the interval-scaled scores of the anxiety questionnaire 
(STAXI X1) was assessed with analysis of variance (univariate 
ANOVA). Where necessary, separate post-hoc t tests were per-
formed for the three genotypes. The p value for the post-hoc t tests 
was adjusted to 0.017 in order to control for the type I error. All 
other test statistics indicating a p value of 0.05 or less were con-
sidered significant. Tests for deviation from Hardy-Weinberg 
equilibrium were performed using an exact test. Data analysis was 
performed using SPSS Statistics, version 19.
 Results
 A total of 1,094 subjects (550 current smokers and 
544 never-smokers) were genotyped for SNP rs16147. 
Mean age was 34.7  8 12.8 years. SNP rs16147 did not 
deviate from Hardy-Weinberg equilibrium (TT = 257, 
23.6%, CT = 557, 51.1%, and CC = 277, 25.4%; for non-
smokers p = 0.086, for smokers p = 0.444). Sociodemo-
graphic and clinical characteristics of the study popula-
tion are presented in  table 1 .
 We found a significant difference in the number of al-
lele carriers between the group of smokers and non-
smokers:   2  analysis revealed a significantly higher prob-
ability for TT genotype of being a smoker compared to 
being a non-smoker (  2  = 4.74; p = 0.029). However, com-
parisons of CC and CT alleles between the two groups did 
not show significant differences (CC: d.f. = 1, p = 1.0; CT: 
d.f. = 1, p = 0.271) ( fig. 1 ;  table 2 ). The ratio between smok-
 Table 1. D emographic information
 Parameters  Entire sample
 (n = 1,094)
 mean (SD) 
 Smokers
 (n = 550)
 mean (SD) 
 Never-smokers
 (n = 544)
 mean (SD) 
 Age, years  34.66 (12.81)  36.54 (12.88)  32.76 (12.47) 
 Females, %  57.6  53.8  61.4 
 Years of school education  11.79 (1.59)  10.38 (1.70)  12.19 (1.34) 
 Exhaled CO, ppm  7.7 (10.21)  13.52 (11.61)  1.72 (1.53) 
 Plasma cotinine, ng/ml  51.76 (133.72)  99.60 (155.23)  3.48 (83.63) 
 FTND  –  2.94 (2.70)  – 
 Cigarettes per day  –  13.67 (10.39)  – 
 Age of onset, years  –  16.11 (3.23)  – 
 Cigarettes per lifetime  –  112,980.77 (108,741.15)  – 
 AUDIT  4.03 (3.43)  4.89 (3.84)  3.16 (2.69) 
 BMI  24.26 (4.68)  24.66 (5.09)  23.86 (4.18) 
 STAI-X1 state  34.23 (8.05)  35.02 (8.61)  33.43 (7.38) 
 STAI-X2 trait  35.38 (9.18)  35.90 (9.61)  34.85 (8.69) 
 SD = Standard deviation; AUDIT = alcohol use disorders identification text (Babor et al., 1992 [48); BMI = 
body mass index; FTND = Fagerström Test for Nicotine Dependence (level of nicotine dependence, Heatherton 
et al., 1991 [32; German version: Bleich et al., 2002 [49); STAI = State-Trait Anxiety Inventory (Spielberger, 
1970 [37). 
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ers and non-smokers in CC/CT allele carriers is 0.94, 
while the ratio between smokers and non-smokers in TT 
allele carriers is 1.28. The OR and CI for CC/CT com-
pared to TT allele carriers is OR = 0.732, CI = 0.553–
0.970.
 In an omnibus interaction analysis, smokers com-
pared to non-smokers showed a significantly higher state 
anxiety score (STAI X1) (F = 11.790; d.f. = 1; p = 0.001) 
but not trait anxiety score (STAI X2) (F = 2.833; d.f. = 1; 
p = 0.093). This effect was specifically accentuated within 
the TT allele carriers: the interaction effect (smoking sta-
tus  ! genotype) indicates significantly higher scores of 
the STAI X1 questionnaire in TT allele carriers who 
smoked compared to the TT allele carriers who never 
smoked (F = 3.317; d.f. = 2; p = 0.037). This effect was post-
hoc additionally and separately tested for the three geno-
types and resulted in a highly significant difference be-
tween smokers and non-smokers in the TT allele carriers 
(T = 3.590; p  ! 0.000) ( fig. 2 ). However, this interaction 
effect (smoking status  ! genotype) was not found con-
cerning trait anxiety (STAI X2) (F = 1.213; d.f. = 1; p = 
0.298).
 We did not observe significant differences between the 
different alleles of the SNP rs16147 concerning the age of 
onset of tobacco dependence, FTND scores, pack-years, 
amount cigarettes smoked per day, and tobacco craving 
(QSU) (data not shown).
 Table 2. G enotype and smoking status
 SNP rs16147  n  2  p 
 CC smokers  139  0.000  1.000 
 CC non-smokers  139 
 CT smokers  266  1.211  0.271 
 CT non-smokers  292 
 TT smokers  145  3.969  0.046 
 TT non-smokers  113 
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 Fig. 1. Number of subjects analyzed for the SNP rs16147 (smokers 
vs. non-smokers): TT = 257, 23.6%, CT = 557, 51.1%, and CC = 277, 
25.4%.  *  TT allele carriers had a significantly higher probability 
of being a smoker compared to being a non-smoker (p  ! 0.05). CC 
and CT alleles between the two groups did not show significant 
differences (p  1 0.05). 
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 Fig. 2. Scores of the STAI1 questionnaire (smokers vs. non-smok-
ers).  *  There are significantly higher scores of the STAI1 question-
naire in TT allele carriers who smoked compared to the TT allele 
carriers who never smoked (p  ! 0.05). Comparisons of CC and
CT alleles between the two groups did not show significant dif-
ferences (p  1 0.05). 
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 Discussion
 The main result of our study is the finding that the risk 
variant of the SNP rs16147 (TT allele), located in the NP-Y 
gene promoter, is associated with increased probability of 
tobacco smoking behavior. TT allele (rs16147) carriers 
have a significantly higher probability of being a smoker, 
compared to CC and CT allele carriers. However, we did 
not find differences concerning the age of onset of tobac-
co dependence, amount of cigarettes smoked per day, and 
tobacco craving (QSU) between the different genotypes. 
 Numerous studies on the effects of rs16147 on NP-Y gene 
expression have been reported in the literature, reporting 
rather mixed and conflict results  [24, 44–46] . However, 
the C allele was identified as the high NP-Y expressing al-
lele in most reports. Our results are consistent with re-
ports suggesting that TT allele carriers (rs16147) show re-
duced gene expression of the anxiolytic protein NPY. We 
found significantly higher scores of the STAI1 question-
naire in TT allele carriers who smoked compared to the 
TT allele carriers who never smoked. Recently published 
data support our results, reporting the T allele of rs16147 
is associated with anxiety and depressive symptoms in 
young adults  [24, 29] . This might be a consequence of the 
reduced gene expression of the anxiolytic protein NPY in 
T(T) allele carriers (rs16147). It is well known that patients 
with psychiatric disorders (e.g. anxiety disorders) have a 
higher risk to develop tobacco dependence. In addition to 
shared genetic risk factors of psychiatric dis orders and to-
bacco dependence, the anxiety and stress attenuation ef-
fects of nicotine are known to play an important role
in the development of tobacco addiction.  Especially in 
pathophysiological mechanisms of anxiety/depression 
and substance abuse, NP-Y has been implicated repeat-
edly  [20, 26–28, 47] . Since the biological effects of NP-Y 
are substantially controlled by the NP-Y gene, the in-
creased state anxiety and associated risk of tobacco smok-
ing might be a compensation of the impaired NP-Y ex-
pression of TT allele carriers (rs16147). This hypothesis is 
based on the observation that NPY has an important 
function in counter-regulating states of anxiety  [20] .
 Taken together, our results suggest an involvement of 
the NPY system in tobacco smoking. We found individu-
als carrying the risk genotype TT of rs16147, associated 
with reduced NP-Y levels in former studies, have signifi-
cantly higher state anxiety and have a higher individual 
vulnerability for tobacco smoking. However, the TT al-
lele of rs16147 was not associated with higher tobacco 
craving, earlier age of onset of tobacco dependence, and 
higher amount of cigarettes smoked per day, implying ad-
ditional risk factors which contribute to the complex dis-
ease of tobacco dependence. Our study has some limita-
tions: Whether rs16147 directly or indirectly influences 
NP-Y expression, or whether it acts through other path-
ways has not been investigated so far and should be tar-
geted in further studies. However, in our large case-con-
trol study, we found that a mutation in the NP-Y gene 
promoter may constitute a genetic risk factor for tobacco 
dependence. Further studies are needed to replicate our 
findings and to further elucidate other genetic risk vari-
ants of tobacco dependence.
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